The target of our product is a receptor named CD31 or PECAM1. Giuseppina Caligiuri and Antonino Nicoletti the lead researchers and co-founders of the company highlighted is role in the modulation of the immune response. CD31 is expressed on all the immune cells and on endothelial cells which confers to our product its holistic mechanism of action.